Key result
Extended edoxaban treatment for 6 or 12 months significantly reduced the recurrence rate of venous thromboembolism to 5.78% compared to 13.91% with 3-month treatment, without increasing major bleeding.
Why the study?
Cancer patients face elevated VTE risk and DOACs have become controversial therapies, warranting evaluation of edoxaban across different treatment durations.
Does edoxaban for 6 or 12 months reduce recurrent VTE compared to 3 months in cancer patients with VTE?
Meta-Analysis (n=3,190)
Does edoxaban for 6 or 12 months reduce recurrent VTE compared to 3 months in cancer patients with VTE?
Absolute Event Rate: 5.78% vs 13.91%
p-value: p=<0.001
Extended treatment with edoxaban for 6 or 12 months significantly reduces VTE recurrence in cancer patients compared to 3 months, without increasing the risk of major bleeding.
Supports extended edoxaban in cancer-associated VTE; reinforces benefit of prolonged therapy without excess bleeding.
No takes yet. Share an insight, caveat, or question.
Kakamad et al. (2024) conducted a meta-analysis in Cancer-associated venous thromboembolism (n=3,190). Edoxaban (6 or 12 months) vs. Edoxaban (3 months) was evaluated on Recurrent venous thromboembolism (VTE) (p=<0.001). Extended edoxaban treatment for 6 or 12 months significantly reduced the recurrence rate of venous thromboembolism to 5.78% compared to 13.91% with 3-month treatment, without increasing major bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: